Wedbush Securities Inc. purchased a new position in UiPath Inc. (NASDAQ:PATH) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,663 shares of the healthcare company’s stock, valued at approximately $245,000.
A number of other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD acquired a new position in UiPath in the second quarter worth about $1,521,290,000. ARK Investment Management LLC acquired a new position in UiPath in the second quarter worth about $806,729,000. Coatue Management LLC acquired a new position in UiPath in the second quarter worth about $769,807,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in UiPath in the second quarter worth about $409,526,000. Finally, Nikko Asset Management Americas Inc. acquired a new position in UiPath in the second quarter worth about $411,517,000. Institutional investors and hedge funds own 31.82% of the company’s stock.
NASDAQ PATH opened at $49.16 on Thursday. UiPath Inc. has a twelve month low of $46.66 and a twelve month high of $90.00. The firm’s 50 day moving average price is $52.58 and its two-hundred day moving average price is $61.80.
In other UiPath news, insider Brad Brubaker sold 13,400 shares of UiPath stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $56.68, for a total transaction of $759,512.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Dines sold 20,964 shares of UiPath stock in a transaction on Friday, November 12th. The shares were sold at an average price of $56.39, for a total transaction of $1,182,159.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 401,357 shares of company stock worth $22,592,750. Corporate insiders own 28.60% of the company’s stock.
A number of equities analysts have issued reports on PATH shares. Cowen cut their target price on shares of UiPath from $80.00 to $72.00 and set an “outperform” rating on the stock in a report on Friday, October 8th. They noted that the move was a valuation call. Royal Bank of Canada cut their target price on shares of UiPath from $74.00 to $65.00 and set a “sector perform” rating on the stock in a report on Thursday, October 7th. Credit Suisse Group began coverage on shares of UiPath in a report on Tuesday, November 16th. They issued an “outperform” rating and a $75.00 target price on the stock. Canaccord Genuity raised UiPath to a “hold” rating and cut their price target for the company from $75.00 to $65.00 in a report on Wednesday, September 8th. Finally, BMO Capital Markets cut their price target on UiPath from $85.00 to $70.00 and set a “market perform” rating on the stock in a report on Wednesday, September 8th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $71.00.
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows.
Further Reading: How do taxes affect a CDs total return?
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.